ArticleEuropean journal of nuclear medicine and molecular imaging2025
[
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Diagnostic accuracy of SPECT/CT in parathyroid adenoma detection: impact of radiopharmaceutical choice and quality control practices.EJNMMI reports · 2026Article
- MR Pulse Sequences for Parathyroid Adenoma Imaging Using [Nuclear medicine and molecular imaging · 2026Article
- Molecular Imaging in Parathyroid Carcinoma Management: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate preoperative localization of hyperfunctioning parathyroid glands is essential for enabling a focused surgical approach in patients with primary hyperparathyroidism (pHPT). Our study aims to determine the diagnostic value of 18F-fluorocholine positron emission tomography/magnetic resonance imaging ([18F]FCH PET/MRI) and [18F]FCH PET/computed tomography (PET/CT) in identifying parathyroid adenomas.
methodsWe conducted a retrospective study to assess the diagnostic accuracy of [18F]FCH PET/MRI and [18F]FCH PET/CT as first- and second-line methods for detecting parathyroid adenomas in patients with pHPT. The primary endpoints included patient-based sensitivity, specificity, and positive predictive value (PPV), with intraoperative surgical localization and histopathological analysis serving as reference, i.e., gold standard.
resultsThe study included 322 patients. A total of 264 patients underwent [18F]FCH PET/MRI, thereof 155 and 109 as a second- and first-line method, respectively. [18F]FCH PET/CT was performed in 58 patients, thereof 44 and 14 in a second- and first-line setting, respectively. Total sensitivity, specificity, PPV, negative predictive value (NPV), and diagnostic accuracy of [18F]FCH PET/MRI were 0.967, 0.818, 0.983, 0.692, and 0.955, respectively, while the same parameters for [18F]FCH PET/CT were 0.980, 0.875, 0.980, 0.875, and 0.966, respectively (all p > 0.05). There was also no difference between the two methods in the first- or second-line imaging scenarios.
conclusionBoth [18F]FCH PET/MRI and [18F]FCH PET/CT are highly accurate imaging modalities for localizing parathyroid adenomas in both first- and second-line settings. They can be regarded as “top-scoring” or “one-stop-shop” techniques for preoperative assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.